Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cannabis for the Treatment of Epilepsy: an Update
Tyler E. Gaston, Jerzy P. Szaflarski
Current Neurology and Neuroscience Reports (2018) Vol. 18, Iss. 11
Closed Access | Times Cited: 135

Showing 1-25 of 135 citing articles:

Diversity of molecular targets and signaling pathways for CBD
Douglas Lamounier de Almeida, Lakshmi A. Devi
Pharmacology Research & Perspectives (2020) Vol. 8, Iss. 6
Open Access | Times Cited: 192
Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy
Valentina Franco, Emilio Perucca
Drugs (2019) Vol. 79, Iss. 13, pp. 1435-1454
Closed Access | Times Cited: 147
Cannabis: a multifaceted plant with endless potentials
Eric Fordjour, Charles F. Manful, Albert Adu Sey, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 46
Therapeutic Strategies to Ameliorate Neuronal Damage in Epilepsy by Regulating Oxidative Stress, Mitochondrial Dysfunction, and Neuroinflammation
Sahithi Madireddy, Samskruthi Madireddy
Brain Sciences (2023) Vol. 13, Iss. 5, pp. 784-784
Open Access | Times Cited: 42
Cannabidiol activates MAPK pathway to induce apoptosis, paraptosis, and autophagy in colorectal cancer cells
Na Young Kim, Chakrabhavi Dhananjaya Mohan, Gautam Sethi, et al.
Journal of Cellular Biochemistry (2024) Vol. 125, Iss. 4
Closed Access | Times Cited: 20
Medicinal Cannabis—Potential Drug Interactions
Indeewarie Hemamali Dissanayake, Chun Guang Li
Medicines (2018) Vol. 6, Iss. 1, pp. 3-3
Open Access | Times Cited: 149
Hepatotoxicity of a Cannabidiol-Rich Cannabis Extract in the Mouse Model
Laura Ewing, Charles M. Skinner, Charles M. Quick, et al.
Molecules (2019) Vol. 24, Iss. 9, pp. 1694-1694
Open Access | Times Cited: 123
Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy
James W. Wheless, Dennis Dlugos, Ian Miller, et al.
CNS Drugs (2019) Vol. 33, Iss. 6, pp. 593-604
Open Access | Times Cited: 85
Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: a Comprehensive Review
Premalatha Balachandran, Mahmoud A. ElSohly, Kevin P. Hill
Journal of General Internal Medicine (2021) Vol. 36, Iss. 7, pp. 2074-2084
Open Access | Times Cited: 81
A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics
Emily J. Cox, Neha Maharao, Gabriela Patilea-Vrana, et al.
Pharmacology & Therapeutics (2019) Vol. 201, pp. 25-38
Open Access | Times Cited: 79
“Natural” is not synonymous with “Safe”: Toxicity of natural products alone and in combination with pharmaceutical agents
Tyler E. Gaston, Donna L. Mendrick, Mary F. Paine, et al.
Regulatory Toxicology and Pharmacology (2020) Vol. 113, pp. 104642-104642
Open Access | Times Cited: 74
Statement on safety of cannabidiol as a novel food: data gaps and uncertainties
Dominique Turck, Torsten Bohn, Jacqueline Castenmiller, et al.
EFSA Journal (2022) Vol. 20, Iss. 6
Open Access | Times Cited: 49
Analysis of cannabidiol (CBD) and THC in nonprescription consumer products: Implications for patients and practitioners
Owen S. Miller, Edmund J. Elder, Karen J. Jones, et al.
Epilepsy & Behavior (2022) Vol. 127, pp. 108514-108514
Closed Access | Times Cited: 46
Comprehensive Predictions of Cytochrome P450 (P450)-Mediated In Vivo Cannabinoid-Drug Interactions Based on Reversible and Time-Dependent P450 Inhibition in Human Liver Microsomes
Sumit Bansal, Mary F. Paine, Jashvant D. Unadkat
Drug Metabolism and Disposition (2022) Vol. 50, Iss. 4, pp. 351-360
Open Access | Times Cited: 42
Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450
Sumit Bansal, Neha Maharao, Mary F. Paine, et al.
Drug Metabolism and Disposition (2020) Vol. 48, Iss. 10, pp. 1008-1017
Open Access | Times Cited: 67
Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: A randomized controlled trial
Timna Naftali, Lihi Bar‐Lev Schleider, Fabiana Benjaminov, et al.
PLoS ONE (2021) Vol. 16, Iss. 2, pp. e0246871-e0246871
Open Access | Times Cited: 42
Cannabidiol for the treatment of autism spectrum disorder: hope or hype?
João Francisco Cordeiro Pedrazzi, Frederico Rogério Ferreira, Danyelle Silva-Amaral, et al.
Psychopharmacology (2022) Vol. 239, Iss. 9, pp. 2713-2734
Closed Access | Times Cited: 31
Cannabis Pharmacogenomics: A Path to Personalized Medicine
Mariana Babayeva, Zvi G. Loewy
Current Issues in Molecular Biology (2023) Vol. 45, Iss. 4, pp. 3479-3514
Open Access | Times Cited: 17
Higher cannabidiol plasma levels are associated with better seizure response following treatment with a pharmaceutical grade cannabidiol
Jerzy P. Szaflarski, Kathleen Hernando, E. Martina Bebin, et al.
Epilepsy & Behavior (2019) Vol. 95, pp. 131-136
Closed Access | Times Cited: 46
Cognitive function and adaptive skills after a one-year trial of cannabidiol (CBD) in a pediatric sample with treatment-resistant epilepsy
Matthew D. Thompson, Roy C. Martin, Leslie E. Grayson, et al.
Epilepsy & Behavior (2020) Vol. 111, pp. 107299-107299
Closed Access | Times Cited: 42
Pharmacokinetics, efficacy, and safety of cannabidiol in dogs: an update of current knowledge
Alessandra Di Salvo, Maria Beatrice Conti, Giorgia Della Rocca
Frontiers in Veterinary Science (2023) Vol. 10
Open Access | Times Cited: 15
CBD and the 5-HT1A receptor: A medicinal and pharmacological review
Claire Alexander, Jiyoon Jeon, Kyle Nickerson, et al.
Biochemical Pharmacology (2025) Vol. 233, pp. 116742-116742
Closed Access
Characteristics of Patients Admitted to the Medical Ward with a Positive Urine Test for Cannabis: A Medical Center Experience
George Habib, Uriel Levinger, Mohammad Haydar, et al.
Open Journal of Internal Medicine (2025) Vol. 15, Iss. 01, pp. 1-7
Open Access
Drug–drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program
Tyler E. Gaston, E. Martina Bebin, Gary Cutter, et al.
Epilepsy & Behavior (2019) Vol. 98, pp. 201-206
Closed Access | Times Cited: 42
Cognitive functioning following long-term cannabidiol use in adults with treatment-resistant epilepsy
Roy C. Martin, Tyler E. Gaston, Matthew D. Thompson, et al.
Epilepsy & Behavior (2019) Vol. 97, pp. 105-110
Open Access | Times Cited: 41
Page 1 - Next Page

Scroll to top